Trade These, Not Those: Where Smart Money’s Moving on Psychedelics, Live Entertainment, and More

July 31, 2025

DENVER, Colo., Jul 31, 2025 (247marketnews.com)- Two under-the-radar tickers are catching fire for their fundamentals and future-facing narratives: Psyence Biomedical (NASDAQ:PBM) and Venu (NYSE:VENU).

Psyence reported a major milestone through its strategic partner PsyLabs, which successfully produced a GMP-aligned Ibogaine Total Alkaloid (TA) extract. Not only does it meet food-grade microbial safety standards, but it positions PBM at the forefront of the emerging pharmaceutical psychedelics market.

Tony Budden, CEO of PsyLabs, said it best, “We are committed to refining our processes to achieve even higher purity levels, supporting the growing demand for high-quality psychedelic APIs.”

The extract and future high-purity compounds like Ibogaine HCl and Psilocybin Isolate, are expected to reach licensed research institutions and therapeutic developers globally, creating long-term upside for PBM.

VENU is fresh off a 10-day green streak, and started a new one, as VENU is consolidating just below a technical breakout zone at $14, with Cenorium’s price target of $22.30 sparking chatter in momentum circles. CEO J.W. Roth just committed an additional $5 million in personal capital, part of a planned $20 million investment, into VENU’s unique NNN FireSuites platform. The model delivers 11% cap rate real estate income without exposure to insurance, property taxes, or maintenance.

This isn’t your average REIT: VENU blends live entertainment venues with REIT-style cash flow and a $5 billion development pipeline that includes $1 billion already underway.

Onconetix (NASDAQ:ONCO) is a low float, speculative oncology play. It’s still in early stage and needs trial data, but could get very interesting.

Indivior (NASDAQ:INDV) is a steady specialty pharma name.

Norwegian Cruise Line (NYSE:NCLH) is riding the reopening tailwind, but fuel prices could spoil the party.

Alignment Healthcare (NASDAQ:ALHC) is value in the Medicare Advantage space, but government reimbursement pressure is a risk.

TAL Education (NYSE:TAL) is a speculative China edtech recovery play, but geopolitical and regulatory risks are lurking.

VerifyMe (NASDAQ:VRME) was once pitched as a security and authentication play, but it hasn’t captured meaningful market share.

Soligenix (NASDAQ:SNGX) keeps resurfacing on biotech watchlists, but lacks the kind of credible partnerships or trial progress that would justify even speculative bets.

Applied Digital (NASDAQ:APLD) had its AI/crypto infrastructure moment in 2023–24, but has cooled off.

Please click here to read Cenorium’s full Venu analyst report on 247marketnews.com.

For additional 247marketnews.com Siyata disclosure https://247marketnews.com/syta-siyata-mobile-update/ or https://247marketnews.com/venu-disclosure/ for additional VENU disclosure.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (VENU, PBM, ONCO, INDV, NCLH, ALHC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.